Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

Zouhair Souissi

Bibliographie

6 mai 2021

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant – New England Journal of Medicine

The post RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant. appeared first on Links Medicus.

Lu 680 fois

Taille de police Réduire la taille de la police Augmenter la taille de police

Évaluer cet élément

1
2
3
4
5

(0 Votes)

Plus dans cette catégorie : « In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.” Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, »

About Author

Zouhair Souissi

Dernier de Zouhair Souissi

Recherche